The Cydan Team
Vered Bisker-Leib, PhD, MBA
Chief Business Officer
Vered Bisker-Leib brings to Cydan a proven track record in identification, evaluation and execution of licensing and M&A transactions in top tier pharma and biotech companies.
Prior to joining Cydan, Dr. Bisker-Leib worked in an advisory role with both biotech and non-profit organizations. From 2008-2013 Vered was a member of Bristol-Myers Squibb’s Strategic Transactions Group where she assumed positions of increasing responsibility across five therapeutic areas, most recently as an Executive Director and Global Head, Business Development, for the Cardiovascular and Metabolic franchises. She crafted the business development strategy and was responsible for its execution, including the acquisitions of ZymoGenetics, Amira Pharmaceuticals and Amylin.
Previously, Dr. Bisker-Leib also held business development roles at Avalon Pharmaceuticals and MedImmune. She began her professional career as a scientist for Baxter and was co-inventor of five patents related to her work.
Dr. Bisker-Leib received a PhD in Chemical Engineering and an MBA from the University of Massachusetts, Amherst and a BSc in Chemical Engineering from the Israel Institute of Technology, Haifa. As an Israeli native, she served in the Israeli Defense Forces, where she advanced to the rank of First Lieutenant.